Disease · EFO_1000643

infantile epileptic encephalopathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. infantile epileptic encephalopathy. Diseases, record EFO_1000643. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1000643

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: infantile epileptic encephalopathy; Open Targets
Open Targets ID: EFO_1000643; Open Targets
Other names: EIDEE, EIEE, EME, Ohtahara syndrome, early infantile epileptic encephalopathy, early infantile epileptic encephalopathy with suppression-bursts, early myoclonic encephalopathy, early myoclonic encephalopathy with suppression-bursts, early-infantile DEE, early-infantile developmental and epileptic encephalopathy syndrome, epileptic encephalopathy, early infantile, epileptic encephalopathy, infantile; Open Targets
Disease Ontology: DOID:2481; Disease Ontology
MeSH: D013036; MeSH
Highest stage of its drugs: Phase 3, for 2 of its 2 drugs, from ClinicalTrials.gov; Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ZONISAMIDE	CHEMBL750	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	1	Voltage-gated N-type calcium channel alpha-1B subunit blocker	Phase 3	https://conductscience.org/library/genes/774	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6334	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00693017	Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy	Phase 3	10	2012-09-12	Epilepsy	ZONISAMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00150748	Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy	Phase 3	217		Generalized Epilepsy	LEVETIRACETAM	Open Targets' reading of its record	ClinicalTrials.gov
NCT00150774	Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults	Phase 3	116		Generalized Convulsive Epilepsy	LEVETIRACETAM	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Zonisamide vs Placebo: serious adverse events	0 of 2	1 of 2	4	NCT00693017

Source Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
19327967	RESULT	1	PubMed
18285535	RESULT	1	PubMed
22050371	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1000643

GET https://conductscience.org/api/diseases/v1/EFO_1000643/drugs

API reference For AI assistants